Privi Speciality Chemicals Q1 FY27: Revenue up 20% to ₹681 Cr, Merger progressing
Privi Speciality Chemicals reported Q1 FY27 revenue of ₹681.42 crore, up 20% YoY. EBITDA was ₹167.47 crore, up 18.73%, with margins at 24.58%. Profit after tax was ₹83.2 crore. The company is progressing with its merger plan, expected to complete this financial year. Phase-1 capacity expansion to 54,000 MT is nearing completion.
The strong financial performance, coupled with significant corporate actions like the merger and capacity expansion, are material events that are expected to have a substantial impact on the company's future growth and operational structure.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, along with maintaining healthy EBITDA margins. Progress in expansion projects and the ongoing merger also contribute positively.
Privi Speciality Chemicals Limited reported a strong start to FY27 with Q1 revenue growing 20.01% year-on-year to ₹681.42 crore. EBITDA for the quarter stood at ₹167.47 crore, a 18.73% increase, with EBITDA margins maintained at 24.58%. Profit after tax was ₹83.2 crore, up from ₹61.46 crore in Q1 FY26.
The company highlighted healthy demand across domestic and international markets, benefiting from global customers' focus on supply chain diversification and dependable sourcing. Key operational highlights include progress on expansion projects and product development for high-value specialty molecules. The joint venture PRIGIV also continued to make steady progress.
Significant corporate developments include the progress on the merger of Privi Speciality Chemicals Limited, Privi Fine Sciences Private Limited, and Privi Biotechnologies Private Limited, aimed at simplifying the group structure and enhancing synergies. The company has filed the scheme with the NCLT, with completion expected within the financial year.
Capital expenditure updates indicate that Phase-1 of production capacity expansion, increasing capacity from 48,000 to 54,000 metric tons, is expected to be commercialized shortly. Phase-2 and Phase-3 of the multi-specialty aroma chemicals project are also progressing as planned. The company reiterated its vision to achieve ₹5,000 crore in revenue and over ₹1,000 crore of EBITDA in the next three to four years.
What to do with a filing like this
Privi Speciality Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Privi Speciality Chemicals Limited. Read the original for the full detail.